Introduction
============

*Infection & Chemotherapy* (ISSN: 2093-2340) is the official journal of both the Korean Society of Infectious Diseases and the Korean Society for Chemotherapy. It has been a continuation of the journal Kamyŏmgwa hwahak yopŏp (ISSN: 1598-8112), which started in 2003 and ended in 2009, *Infection & Chemotherapy* is the result of a merge between Taehan Hwahak Yopŏp Hakhoe chi (= *The Journal of the Korean Society for Chemotherapy*, ISSN: 1225-7850) which started in 1983 and ended in 2002 and Kamyŏm (= *Korean Journal of Infectious Diseases*, ISSN: 0368-6221) which started in 1969 and ended in 2002. *Infection & Chemotherapy* is the typical model in Korea for a merger between two society journals. It changed the main language of its articles into English from 2013 onwards so that they could be submitted to PubMed Central after the production of full-text JATS XML files \[[@B1]\]. Furthermore, it is searchable from PubMed. Its content has been also searchable from the Web of Science Core Collection in the Emerging Sources Citation Index database since its 2015 issues and from Scopus since its 2011 issues. Therefore, one can rightly claim that it is an international journal. I would like to present the recent status of journal metrics for *Infection & Chemotherapy* to confirm its present position as an international journal, and furthermore, to introduce the recent publishing policies or guidelines to better transparency of authorship and scientific integrity.

Materials and Methods
=====================

As for journal metrics, the following will be analyzed from the Web of Science Core Collection: the number of citable and non-citable articles, the nationality of authors, the nationality of editorial board members, the proportion of funded articles to original articles, total citations, the manually calculated impact factor \[[@B2]\], the authors\' countries and source title of the articles which cited *Infection & Chemotherapy*, and the Hirsch index \[[@B3]\]. The definition of the impact factor is given as the "impact factor of the journal J in the year X = A/B, where A is the number of total citations in the year X received by all items published in the journal J in the years (X−1) and (X−2) and B is the total number of all citable items published in the journal J in the years (X−1) and (X−2). Citable items include only papers and reviews and do not include errata, editorials, and abstracts. In the counting of A, however, citations to all items published in J are included" \[[@B2]\]. The Hirsch index is defined as "the number of papers with citation number ≥h, and it has index h if h of its Np papers have at least h citations each, and the other (Np--h) papers have ≤h citations each" \[[@B3]\].

Recent policy or standards that were introduced included author taxonomy, an open data policy, a clinical data sharing policy, and the "principles of transparency and best practice in scholarly publishing 3rd edition".

Results
=======

1. Journal metrics {#sec1}
------------------

The number of citable and non-citable articles is presented in [Fig. 1](#F1){ref-type="fig"}. Out of 181 articles, the highest number of authors are from Korea (165, 91.2%). There are articles from 11 other countries ([Fig. 2](#F2){ref-type="fig"}). Out of 51 editorial board members, 30 members are from Korea ([Fig. 3](#F3){ref-type="fig"}). 21 members are from 16 other countries. The proportion of funded articles to original articles has increased yearly to reach 46.7% in 2018 ([Fig. 4](#F4){ref-type="fig"}). Total citations increased yearly ([Fig. 5](#F5){ref-type="fig"}). The number of citable articles from 2015 to 2016 was 81 and the number of citations in 2017 in the articles published between 2015 and 2016 was 140. Therefore, the manually calculated impact factor of 2017 was 1.728 (140/81). The number of countries that cited articles of the 2015--2018 issues of *Infection & Chemotherapy* was 60. Korea, the United States of America, and China were the top 3 countries that cited the journal ([Fig. 6](#F6){ref-type="fig"}). The 196 source journal titles that cited the 2015--2018 issues of *Infection & Chemotherapy* are presented in [Fig. 7](#F7){ref-type="fig"}. Out of 346 citing articles, 49 (14.2%) were from *Infection & Chemotherapy*. The Hirsch index can be obtained from [Table 1](#T1){ref-type="table"} which shows the most frequently cited articles published from 2003. A total of 582 articles had been cited in the Web of Science Core Collection. The Hirsch index is 15 ([Table 1](#T1){ref-type="table"}).
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###### Most frequently cited articles of *Infection & Chemotherapy* out of 582 cited articles from 2003

![](ic-50-219-i001)

  Rank   Authors\' country   Title                                                                                                                                                                              Year   Vol   Page   Publication type   Times cited
  ------ ------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------ ----- ------ ------------------ -------------
  1      USA                 Cytomegalovirus Infections in Solid Organ Transplantation: A Review                                                                                                                2013   45    260    Review             68
  2      Korea               Praziquantel Treatment in Trematode and Cestode Infections: An Update                                                                                                              2013   45    32     Review             51
  3      Korea               Antimicrobial Resistance in Asia: Current Epidemiology and Clinical Implications                                                                                                   2013   45    22     Review             50
  4      Korea               Biomarkers of Sepsis                                                                                                                                                               2014   46    1      Review             43
  5      Japan               Genomic Basis for Methicillin Resistance in *Staphylococcus aureus*                                                                                                                2013   45    117    Review             38
  6      Korea               Epidemiology and Characteristics of Metallo-β-Lactamase-Producing *Pseudomonas aeruginosa*                                                                                         2015   47    81     Review             35
  7      Korea               Therapy of Infections due to Carbapenem-Resistant Gram-Negative Pathogens                                                                                                          2014   46    149    Review             31
  8      Korea               Diagnosis of Pneumococcal Pneumonia: Current Pitfalls and the Way Forward                                                                                                          2013   45    351    Review             30
  9      Korea               Epidemiology and Clinical Features of Post-Transplant Bloodstream Infection: An Analysis of 222 Consecutive Liver Transplant Recipients                                            2013   45    315    Original article   28
  10     USA                 Fluad^®^-MF59^®^-Adjuvanted Influenza Vaccine in Older Adults                                                                                                                      2013   45    159    Review             21
  11     Korea               Increase in the Prevalence of Carbapenem-Resistant Acinetobacter Isolates and Ampicillin-Resistant Non-Typhoidal *Salmonella* Species in Korea: A KONSAR Study Conducted in 2011   2014   46    84     Original article   19
  12     USA, Korea          Clinical Importance and Epidemiology of Quinolone Resistance                                                                                                                       2014   46    226    Review             18
  13     Korea               Epidemiology and Clinical Features of Bloodstream Infections in Hematology Wards: One Year Experience at the Catholic Blood and Marrow Transplantation Center                      2013   45    51     Original article   18
  14     UK                  Revolutionising Bacteriology to Improve Treatment Outcomes and Antibiotic Stewardship                                                                                              2013   45    1      Review             18
  15     Korea               Blood Stream Infections in Patients in the Burn Intensive Care Unit                                                                                                                2013   45    194    Review             15

2. New policies or guidelines {#sec2}
-----------------------------

### 1) Author (contributor) taxonomy

In 2012, a group of journal editors met under the support of Harvard University and Welcome Trust. They discussed the descriptions of each author\'s role in the list of authors. *Nature* published a commentary on author taxonomy in 2014 which mentioned that "through the endorsement of individuals\' contributions, researchers can start to move beyond 'authorship' as the dominant measure of esteem" \[[@B4]\]. Since 2014, author taxonomy -- otherwise known as CRediT (Contributor Roles Taxonomy) -- started to be adopted by journal editors and publishers. The authors\' role was classified into 14 categories from conceptualization to writing-review and editing; these categories are available at: <https://casrai.org/credit/>. In Korea, a number of journals including the *Journal of Educational Evaluation for Health Professions* began to adopt author taxonomy in 2017 \[[@B5]\]. An example is as follows:

Authors\' contributions

Conceptualization: SH. Data curation: MKY. Formal analysis: EYL. Funding acquisition: SH. Methodology: EYL MKY SH. Project administration: SH. Visualization: EYL MKY SH. Writing - original draft: EYL. Writing - review & editing: EYL MKY SH.

This kind of description may be able to reduce disputes over authorship and give specific credit to each author. It is not necessary to adopt or describe all 14 categories. The range of description is dependent on the specific characteristics of the articles.

### 2) Open data policy

It was originally designed for the transparent presentation of public data supported or generated by the government. Therefore, it is also called "open public sector information" \[[@B6]\]. It was first initiated by the United States of America and the European Union governments. The Korea government also adopted the open data policy for the databases generated by the government\'s budget after enacting the law "ACT ON PROMOTION OF THE PROVISION AND USE OF PUBLIC DATA" in November 19 2014, available at: <https://elaw.klri.re.kr/kor_service/lawView.do?hseq=47133&lang=ENG>. Recently, this concept was introduced to scholarly journal publishing. At the 13th European Association of Science Editors\' conference in Strasbourg, France in 2016, Lex M. Bouter proposed "increasing transparency with open data policies and modifications of the reward system for researchers in order to prevent questionable research practices or sloppy science" \[[@B7]\]. In Korea, the *Journal of Educational Evaluation for Health Professions* is a pioneer in its adoption of the open data policy in March 2016 \[[@B8]\]. The open data policy was already introduced in the field of biomedical information; therefore, to publish articles on genes or proteins, researchers should deposit their data to GenBank or other related banks managed by the United States National Center for Biotechnology Information. These data can thus be used for review and further analysis by researchers in the same field. Depositing data and opening them up to other researchers can provide three benefits. First, scientific soundness can be guaranteed. If raw data are opened to reviewers and readers, the analysis of data can be repeated with the same methods more easily. Second, there is a possibility of developing new ideas through raw data; furthermore, this can initiate more advanced research in the same field. Third, raw data can facilitate meta-analysis or high quality systemic reviews through analysis. I am not sure to what extent raw data may be used by researchers because these three benefits are still under speculation. If a journal editor or publisher decides to adopt the open data policy, the depository of data is necessary. Currently, Harvard Dataverse is the first option for society journals \[[@B9]\]. Until August 4 2018, 76 journals have made their own space for data deposition (<https://dataverse.harvard.edu/dataverse/harvard>). There is no fee to deposit data. Figshare (<https://figshare.com/>) is the other option for data deposition; however, it is not free.

### 3) ICMJE\'s data sharing statement policy

It is an open data policy. It was recommended by the *International Committee of Medical Journal Editors* (ICMJE); therefore, all journal editors and publishers who state that they follow the ICMJE recommendations should follow this policy. From July 1 2018, manuscripts of clinical trials must announce a data-sharing statement. Editors should add this policy to their instructions to authors. There are options to specify the degree of data sharing statements by authors; therefore, authors can choose from the available options in the examples of data sharing statements which are available from this policy editorial \[[@B10]\].

### 4) Principles of transparency and best practice in scholarly publishing 3rd ed.

This guideline was recently revised in January 2018. Therefore, there are few scholarly journals that adopt this guideline \[[@B11]\]. It is composed of 16 items. Out of 10 scholarly journals published by Trakya University in Turkey, items of marketing, intellectual property, and data sharing were omitted\[[@B12]\]. In Korea, there is still no survey on the compliance of these 16 items to scholarly journals. [Table 2](#T2){ref-type="table"} summarizes the 16 items. It is also mandatory to fulfill these 16 items before applying to be indexed in MEDLINE \[[@B13]\].

###### Compliance of a medical journal to the *Principles of Transparency and Best Practice in Scholarly Publishing* (joint statement by COPE, DOAJ, WAME, and OASPA; (<http://doaj.org/bestpractice>)

![](ic-50-219-i002)

  No.                                Item                                                                                Sub-items
  ---------------------------------- ----------------------------------------------------------------------------------- -------------------------------------
  1                                  Website                                                                             Aims & scope
  Readership                                                                                                             
  Authorship criteria                                                                                                    
  ISSN                                                                                                                   
  2                                  Name of journal                                                                     
  3                                  Peer review process                                                                 Statement of review process
  Method of peer review                                                                                                  
  4                                  Ownership and management                                                            
  5                                  Governing body                                                                      Editorial boards
  6                                  Editorial team/contact information                                                  
  7                                  Copyright and licensing                                                             
  8                                  Author fees                                                                         
  9                                  Process for identification of and dealing with allegations of research misconduct   Step to prevent research misconduct
  COPE\'s guideline                                                                                                      
  10                                 Publication ethics                                                                  Authorship and contributorship
  Complaints and appeal                                                                                                  
  Conflicts of interest                                                                                                  
  Data sharing and reproducibility                                                                                       
  Ethical oversight                                                                                                      
  Intellectual property                                                                                                  
  Post-publication discussions                                                                                           
  11                                 Publishing schedule                                                                 
  12                                 Access                                                                              
  13                                 Archiving                                                                           
  14                                 Revenue sources                                                                     
  15                                 Advertising                                                                         
  16                                 Direct marketing                                                                    

COPE, committee on publication ethics; DOAJ, directory of open access journals; WAME, world association of medical editors; OASPA, open access scholarly publishers association.

Discussion
==========

The metrics results above demonstrate the following. First, although Korean authors are dominant, *Infection & Chemotherapy* has been cited by 60 countries all over the world in 196 journals. Second, the proportion of funded articles has increased yearly. Third, citation has increased yearly and the recent impact factor corresponded to 21.5% of the Journal Citation Reports (JCR) category of infection. Fourth, review articles have been cited more frequently than original articles.

In fact, review articles have been cited more frequently than any other publication types in other journals in Korea, such as *Clinical and Molecular Hepatology* \[[@B14]\], *Clinical and Experimental Vaccine Research* \[[@B15]\], *Annals of Pediatric Endocrinology & Metabolism* \[[@B16]\], *Intestinal Research* \[[@B17]\], and *Neurointervention* \[[@B18]\]. Exceptions were present: *Clinics in Orthopedic Surgery*, where all of the 15 highly-cited articles were original articles, except one \[[@B19]\], and *Blood Research* \[[@B20]\], where out of 10 highly-cited articles, half the type of publication were review articles while the other half were original articles. These phenomena may be dependent on editors\' decisions on how to recruit the invited review articles and from whom the review articles were submitted. In *Infection & Chemotherapy*, Korean authors\' review articles formed a major portion of all the highly-cited articles.

In conclusion, the metrics results tell us the present position of the journal in the international scholarly journal market. This was made possible by the authors\' contribution which were mainly from society members, the editors\' ceaseless devotion, and the publishing society\'s full support. One of the journal\'s present tasks is to recruit more invaluable manuscripts from outside Korea for a multinational authorship. The recent publication policies mentioned above are not difficult for editors to adopt or to describe more lucidly, which will be able to promote the transparency of authorship and the scientific integrity of the articles to the highest level.
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